MedPath

Wells Fargo Lowers Intellia Therapeutics Price Target to $60

Wells Fargo has reduced its price target for Intellia Therapeutics from $70 to $60, maintaining an Overweight rating. The adjustment follows the discontinuation of the Alpha-1 Antitrypsin Deficiency program, with the firm highlighting ATTR amyloidosis with cardiomyopathy as the primary value driver.

Wells Fargo has adjusted its outlook on Intellia Therapeutics (NTLA), lowering the firm’s price target to $60 from $70 while keeping an Overweight rating on the shares. This decision comes in the wake of Intellia Therapeutics discontinuing its Alpha-1 Antitrypsin Deficiency program, a move that Wells Fargo analysts believe is justified given the evolving landscape of gene therapy. The firm emphasizes that ATTR amyloidosis with cardiomyopathy remains the main value driver for Intellia, pointing to the rapid enrollment in the Phase 3 trial as a positive indicator of patient acceptance towards gene editing technologies.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Intellia Therapeutics Announces Strategic Reorganization and 2025 Milestones

Intellia Therapeutics, Inc. (NTLA) has announced a strategic reorganization focusing on its late-stage programs, NTLA-2002 and nex-z, targeting hereditary angioedema (HAE) and transthyretin (ATTR) amyloidosis, respectively. The company also disclosed a 27% workforce reduction and an $8 million restructuring charge. Additionally, Intellia's price target was adjusted by BMO Capital and Wells Fargo, reflecting changes in its strategic direction and clinical trial progress.

Vertex Pharmaceuticals Faces Mixed Outlook for Suzetrigine After Phase 2 Data

Vertex Pharmaceuticals' Suzetrigine showed less promising Phase 2 results for lumbosacral radiculopathy, reducing the probability of success from 50% to 15%.
Despite the LSR setback, optimism remains high for Suzetrigine in acute pain treatment, with anticipated FDA approval based on positive Phase 3 trial outcomes.

Tyra Biosciences Stock Target Adjusted Following Clinical Data Review

H.C. Wainwright has adjusted Tyra Biosciences' stock price target to $30 from $32 while maintaining a Buy rating, following a review of clinical data for its lead compound, TYRA-300. The drug showed promising results in treating non-muscle-invasive bladder cancer and metastatic urothelial carcinoma, with a favorable safety profile.

Acelyrin's Izo Fails Phase 2b/3 Trial in Uveitis; Wells Fargo Adjusts Price Target

Acelyrin's Phase 2b/3 trial of izokibep (izo) in uveitis has failed, leading to the removal of its contribution from Wells Fargo's financial model.
Wells Fargo has lowered its price target for Acelyrin from $15 to $13, while maintaining an Overweight rating on the shares.

Intellia Therapeutics Price Target Lowered by Wells Fargo

Wells Fargo has reduced the price target for Intellia Therapeutics from $80 to $70, while maintaining an Overweight rating on the shares, citing promising Phase 1 ATTR-CM data for nex-z.

Intellia's NTLA-2001 Shows Promise in Early ATTR-CM Trial

Intellia Therapeutics' NTLA-2001 demonstrates potential in stabilizing or improving outcomes for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) patients.
Phase I study data reveals a median five-meter improvement in the six-minute walk test after one year of NTLA-2001 treatment.

Allogene Pauses Cema-Cel Trial Enrollment, Prioritizes Other Programs

Allogene Therapeutics halts new patient enrollment in the Phase 1 ALPHA2 study of cema-cel for relapsed/refractory Chronic Lymphocytic Leukemia (r/r CLL) due to slow enrollment.
Piper Sandler reduces Allogene's price target to $9, excluding cema-cel revenue in CLL from its valuation model, while maintaining an Overweight rating.

PDS Biotech's PDS0101 and Keytruda Combination Therapy to Enter Phase 3 Trial for HPV16-Positive Cancers

PDS Biotechnology is set to initiate the VERSATILE-003 Phase 3 trial in Q1 2025, evaluating the combination of PDS0101 and Keytruda.
The trial will focus on patients with HPV16-positive head and neck squamous cell carcinoma (HNSCC).

Intellia Therapeutics' NTLA-2002 Shows Promise in HAE but Faces Market Concerns

Intellia Therapeutics announced Phase 2 results for NTLA-2002, an investigational gene-editing therapy for hereditary angioedema (HAE), demonstrating a significant reduction in attack rates.
The trial, involving 27 participants, showed a 75% to 81% reduction in monthly HAE attack rates, with a higher dose group experiencing complete response in a majority of patients.

Acelyrin's Izokibep Fails to Meet Primary Endpoint in Phase 2b/3 Psoriasis Trial, Stock Plummets

Acelyrin's stock price plummeted after its investigational drug, izokibep, failed to achieve the primary endpoint in a Phase 2b/3 clinical trial for moderate-to-severe psoriasis.
The trial results were described as "painfully disappointing" by analysts, leading to a significant reduction in the company's price target by Jefferies.

Reference News

[1]
Intellia Therapeutics price target lowered to $60 from $70 at Wells Fargo - Yahoo Finance
finance.yahoo.com · Jan 11, 2025

Wells Fargo reduced Intellia Therapeutics' price target to $60 from $70, maintaining an Overweight rating. The firm view...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy